Roche ’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours

Roche today announced results from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials that showed the investigational personalised medicine entrectinib shrank tumours (objective response rate; ORR) in more than half (57.4%) of people with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumours.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news